Drug Profile


Latest Information Update: 19 Apr 2007

Price : $50

At a glance

  • Originator Luitpold Pharmaceuticals
  • Class
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 19 Apr 2007 Discontinued - Preclinical for Hepatitis B in USA (PO)
  • 31 Oct 2003 Protarga has been acquired by Luitpold Pharmaceuticals
  • 14 Jun 2002 Preclinical trials in Hepatitis B in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top